RECRUITING

Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals

Talk to us

Conditions

Idiopathic Pulmonary Arterial HypertensionHeritable Pulmonary Arterial HypertensionUnaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on EchoHealthy Individuals With no Cardiopulmonary Diseasepulmonary hypertension

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Pulmonary arterial hypertension (PAH) is a severe disease with a delayed diagnosis and markedly elevated mortality. High-risk populations, such as those with known genetic defects, provide a unique opportunity to determine the features of susceptibility and resilience to PAH. This proposal will fundamentally overturn the prevailing understanding of PAH by creating molecularly-driven signatures of susceptibility and resilience, provide novel insight into disease severity, and potentially identify new therapeutic targets. Funding Source - FDA OOPD

Official Title

Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals

Quick Facts

Study Start:2022-11-01
Study Completion:2026-08-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05584722

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:15 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Not specified
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Children and Adults, aged 15 - 80
  2. * Diagnosed with idiopathic or heritable, pulmonary arterial hypertension (PAH), defined according to standard criteria
  3. * Unaffected Mutation Carriers: Healthy participants with a known BMPR2 gene mutation and normal pulmonary pressure and RV function on echo
  4. * Healthy Controls: Healthy individuals without cardiopulmonary disease.
  5. * WHO functional class I-III
  6. * Stable PAH-specific medication regimen for three months prior to enrollment. Subjects with only a single diuretic adjustment in the prior three months will be included. Adjustments in IV prostacyclin for side effect management are allowed.
  1. * Prohibited from normal activity due to wheelchair bound status, bed bound status, reliance on a cane/walker, activity-limiting angina, activity-limiting osteoarthritis, or other condition that limits activity.
  2. * Pregnancy
  3. * Diagnosis of PAH etiology other than idiopathic, heritable
  4. * Functional class IV heart failure
  5. * Requirement of \> 2 diuretic adjustment in the prior three months.

Contacts and Locations

Study Contact

Kelly Burke, RN
CONTACT
(615) 343-4682
kelly.burke@vumc.org
Alisha Lindsey, RT
CONTACT
(615) 343-4682
alisha.lindsey@vumc.org

Principal Investigator

Evan Brittain, MD
PRINCIPAL_INVESTIGATOR
Vanderbilt Medical Center
Anna Hemnes, MD
PRINCIPAL_INVESTIGATOR
Vanderbilt Medical Center
Eric Austin, MD
PRINCIPAL_INVESTIGATOR
Vanderbilt Medical Center

Study Locations (Sites)

Vanderbilt University Medical Center
Nashville, Tennessee, 37232
United States

Collaborators and Investigators

Sponsor: Vanderbilt University Medical Center

  • Evan Brittain, MD, PRINCIPAL_INVESTIGATOR, Vanderbilt Medical Center
  • Anna Hemnes, MD, PRINCIPAL_INVESTIGATOR, Vanderbilt Medical Center
  • Eric Austin, MD, PRINCIPAL_INVESTIGATOR, Vanderbilt Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-11-01
Study Completion Date2026-08-31

Study Record Updates

Study Start Date2022-11-01
Study Completion Date2026-08-31

Terms related to this study

Keywords Provided by Researchers

  • pulmonary hypertension

Additional Relevant MeSH Terms

  • Idiopathic Pulmonary Arterial Hypertension
  • Heritable Pulmonary Arterial Hypertension
  • Unaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo
  • Healthy Individuals With no Cardiopulmonary Disease